
Retired teacher. Figure skating judge. Eurovision fan. Wordle sleuth. Gay introvert. N95 advocate. Still taking every covid precaution I did in 2020. #DavosSafe
- Tweets4.4K
- Following473
- Followers1.3K
- Likes4.1K

ALT In this phase I/II randomized, placebo-controlled trial, a primary series of the vaccine induced persistent immune responses up to 1 year after the second dose.

ALT Fig. 2. Change in immunogenicity status of participants in the NVX-CoV2373 arm (per protocol set). (A) GMTs of anti-SARS-CoV-2 rS serum IgG and (B) serum nAbs against the SARS-CoV-2 ancestral strain on day 1 (before the first vaccine dose) and on days 22 (before the second vaccine dose), 36, 50, 202, and 387. The GMT of serum IgG on day 36 was the primary immunogenicity endpoint of the study. Values next to the data points refer to the number of participants at the time point. Dashed horizontal lines represent correlates of protection titres against symptomatic COVID-19 occurrence as determined by Fong et al.






























